feedback

Course Director

Erika Hamilton, MD
Erika Hamilton, MD

Sarah Cannon Research Institute
Nashville, Tennessee

Faculty

Yelena Y. Janjigian
Yelena Y. Janjigian, MD

Memorial Sloan Kettering Cancer Center
New York, New York

Sandip Patel
Sandip Patel, MD

San Diego Center for Precision Immunotherapy
UC San Diego Moores Cancer Center
La Jolla, California

Nikhil Wagle
Nikhil Wagle, MD

Dana-Farber Cancer Institute/Harvard Medical School
Boston, Massachusetts

Accredited by

Medical Learning Institute, Inc.

View Activity Materials

Activity Description

In this activity, oncology experts explore the potential of the next wave of novel HER2-targeting therapies in various HER2-altered cancers, including breast, gastrointestinal, lung, and other tumors. Watch as the panel share their insights into the data that support therapeutic targeting of HER2 and consider other critical research questions and future directions.

Target Audience

This activity has been designed to meet the educational needs of oncologists, cancer research scientists, and other healthcare professionals involved in the care of patients with advanced/metastatic HER2-expressing and ERBB2-mutant cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Review evidence-based guidelines and expert recommendations regarding HER2 testing and interpretation of results in breast, gastric, colorectal, and non–small cell lung cancers
  • Evaluate the characteristics, mechanisms of action, and efficacy/safety evidence of established and emerging HER2-targeted agents for the management of patients with advanced HER2-expressing or ERBB2-mutant cancers
  • Identify novel approaches to overcome mechanisms of resistance to HER2-targeted therapies
  • Integrate the latest HER2-targeted therapies into individualized treatment plans for patients with advanced HER2-expressing or ERBB2-mutant breast, gastric, colorectal, and non–small cell lung cancers, either in the context of clinical practice or through clinical trial participation

Providership, Credit, and Support


This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Puma Biotechnology, and Seattle Genetics.

Physician Continuing Medical Education

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Chair
Erika Hamilton, MD
Director, Breast and Gynecologic Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Erika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Black Diamond Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd; Lilly; Mersana Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma Biotechnology, Inc; and Silverback Therapeutics. Consulting fees paid to institution only.
Grant/Research Support from AbbVie; Acerta; Aravive, Inc.; ArQule; AstraZeneca; Arvinas; BerGenBio; Black Diamond Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics, Inc; Clovis Oncology, Inc.; Cytomx; Curis, Inc.; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Effector; Eisai Inc.; EMD Serono; Fochon Pharmaceuticals; FujiFilm; Genentech, Inc./F. Hoffmann-La Roche Ltd; Harpoon Therapeutics; H3Biomedicine; Hutchison MediPharma; Immunomedics; InventisBio; Leap Therapeutics; Lilly; Lycera; MacroGenics, Inc.; MedImmune; Medivation; Mersana Therapeutics, Inc.; Merus; Millennium; Molecular Templates; Novartis Pharmaceuticals Corporation; NuCana; OncoMed Pharmaceuticals, Inc.; Orinove; Radius Health; Regeneron Pharmaceuticals, Inc.; Rgenix; Pfizer Inc.; Silverback Therapeutics; Stemcentrx; Syndax Pharmaceuticals Inc.; Sermonix Pharmaceuticals; Sutro; Syros; Taiho Pharmaceutical Co., Ltd.; TapImmune Inc.; Tesaro; The Takeda Pharmaceutical Company Limited; Torque; Unum Therapeutics; Verastem Oncology; Zenith Epigenetics Ltd.; and Zymeworks Inc. (Research/Clinical Trial Support paid to institution).

Faculty
Yelena Y. Janjigian, MD
Associate Attending Physician
Associate Professor, WCMC
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Yelena Y. Janjigian, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Imugene Limited; Jounce Therapeutics, Inc.; Lilly; Merck & Co., Inc.; Michael J. Hennessy Associates, Inc.; Paradigm Medical Communications LLC; Pfizer Inc.; Seattle Genetics, Inc.; and Zymeworks Inc.
Grant/Research Support from Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd; Lilly; Merck & Co., Inc.; and Ono Pharmaceutical Co., Ltd.
Stock Shareholder in Rgenix, Inc.

Sandip Patel, MD
Associate Professor
Co-Leader, Experimental Therapeutics
Deputy Director, San Diego Center for Precision Immunotherapy
Director, Clinical Trials Office
Division of Hematology and Oncology, Department of Medicine
UC San Diego Moores Cancer Center
La Jolla, California

Sandip Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca/MedImmune; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd; Illumina, Inc.; Lilly; Rakuten Medical Inc.; and Tempus Labs, Inc.

Nikhil Wagle, MD
Assistant Professor of Medicine
Dana-Farber Cancer Institute/Harvard Medical School
Boston, Massachusetts

Nikhil Wagle, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Lilly and Relay Therapeutics.
Grant/Research Support from Puma Biotechnology, Inc.
Stock Shareholder in Relay Therapeutics.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Natalie I. Vokes, MD
Patricia A. Ensor, RPh, MBA

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC credit. There are no prerequisites and there is no fee to participate in this activity or to receive MOC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/MOC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.